Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
|Videos|May 6, 2015
Instances Where a Patient Benefits Directly From a Physician-Pharmacist Collaboration
Reid Blackwelder, MD, FAAFP, of the East Tennessee State University Family Physicians clinic, and chairman of the American Academy of Family Physicians, gives some examples of instances where a patient benefited directly from a physician-pharmacist collaboration.
Advertisement
Reid Blackwelder, MD, FAAFP, of the East Tennessee State University Family Physicians clinic, and chairman of the American Academy of Family Physicians, gives some examples of instances where a patient benefited directly from a physician-pharmacist collaboration.
This video was recorded at APhA’s Annual Meeting and Exposition in March 2015.
Advertisement
Related to this article
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
5